• Corpus ID: 9530939

Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits.

  title={Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits.},
  author={Remigiusz Zieba and Malgorzata Wagrowska-Danilewicz},
  journal={Polish journal of pharmacology},
  volume={55 6},
The aim of this study was to establish the effect of naturally occurring antioxidant carnosine (CAR) on the doxorubicin (DOX)-induced cardiotoxicity in a rabbit model. For this purpose, we evaluated the influence of DOX administration alone and in a combined therapy with CAR on the hemodynamic parameters and on the degree of cardiac muscle cell alterations in rabbits. Thirty one chinchilla rabbits were divided into four groups. One group of rabbits was injected iv with DOX at a dose of 2 mg kg… 

Figures and Tables from this paper

Amifostine improves hemodynamic parameters in doxorubicin-pretreated rabbits.

It is shown that pretreatment with doxorubicin at the total dose of 12 mg/kg significantly reduced CI and increased TPR in doxorbicin-pretreated rabbits, and amifostine improved CI and TPR on average in these animals.

Protective effect of carnosine on adriamycin-induced oxidative heart damage in rats.

An increase in oxidative stress, superoxide dismutase, glutathione peroxidase levels, catalase inactivation and cardiac dysfunction induced by adriamycin were prevented by carnosine.

Beneficial effects of carnosine and carnosine plus vitamin E treatments on doxorubicin-induced oxidative stress and cardiac, hepatic, and renal toxicity in rats

The results may indicate that CAR alone, especially in combination with Vit E, protect against DOX-induced toxicity in heart, liver, and kidney tissues of rats.

The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway

Carnosine (β-alanyl-l-histidine), an endogenous dipeptide that is characterized by strong antioxidant, anti-inflammatory, and neuroprotective properties is able to rescue/activate the Nrf2 pathway, as demonstrated by different preclinical studies and preliminary clinical evidence.

Safety evaluation of chicken breast extract containing carnosine and anserine.

Amino acids and derivatives, a new treatment of chronic heart failure?

Recent data suggest that a multi-nutritional approach, including also antioxidants, vitamins, and metals, may be more effective in patients with HF, and larger trials are needed to ascertain safety, efficacy, and impact on prognosis of such an approach in HF.



Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.

  • P. DzięgielZ. Jethon M. Zabel
  • Biology, Medicine
    Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie
  • 2002
Melatonin was found to exert a protective effect on the cardiac muscle cells, which was particularly evident after acute doxorubicin or subchronic daunorubsicin intoxication, using either histological or biochemical methods.

Melatonin as an effective protector against doxorubicin-induced cardiotoxicity.

Melatonin protect against doxorubicin-induced cardiotoxicity without interfering with its antitumor effect, according to the results of the present study.

Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.

DZR is highly effective in attenuating the cardiomyopathy caused by DOX, but dose ratios of DZR:DOX capable of providing total or nearly complete cardioprotection at low doses of DOX are less efficacious at higher doses ofdoxorubicin.

Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity

Observations were interpreted as indicating that the timing of administration of ICRF-187 with respect to that of doxorubicin is an important factor in determining the degree of cardioprotection and that there is a “time window” in which ICRf-187 exerts optimal effects.

European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.

The use of DEX did not add to the toxicity of the anthracyclines, nor was there clear evidence of an adverse impact of the agent on antitumor activity of the chemotherapeutic regimen.

Pathogenesis and prevention of doxorubicin cardiomyopathy.

A greatly delayed type of doxorubicin cardiotoxicity has been recently found to occur in survivors of childhood cancers who were treated with doxorbicin without any immediate adverse effects, but develop chronic cardiomyopathy at periods of time ranging up to 15 years later.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

  • S. SwainF. Whaley R. Gams
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
DZR is the first agent shown to reduce cardiotoxicity from doxorubicin and had a significant cardioprotective effect as measured by noninvasive testing and clinical CHF.

[Cardiac toxicity in cancer therapy].

The aim of this article is to review the mechanism of chemotherapy- and radiation-induced cardiac toxicity, diagnostic procedures and methods of reducing this toxicity, and the use of pharmacological protection with dexrazoxane remains controversial.

Cytoprotective agents for anthracyclines.

  • R. Dorr
  • Biology, Chemistry
    Seminars in oncology
  • 1996
In tumor-bearing mice, amifostine reduces the lethality of high doses of doxorubicin without affecting antitumor activity, and in vitro studies in neonatal rat heart cells have shown direct evidence of anthracycline cardioprotection for both am ifostine and WR-1065.